tbuckley/cabot-search huggingface dataset:
US Preventive Services Task Force Recommendation Statement on Screening for Colorectal Cancer
Authors: Shida Haghighat, Daniel A. Sussman, Amar Deshpande
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
1553TiP A phase III study comparing the efficacy of the combination of doxorubicin and the tumor-targeting human antibody-cytokine fusion protein L19TNF to doxorubicin alone as first-line therapy in patients with advanced or metastatic soft tissue sarcoma
Authors: C. Schliemann, D. Pink, A. Flörcken, M. Ahrens, G. Egerer, K. Götze, E. Palmerini, S. Stacchiotti, G. Grignani, P. Rutkowski, R. Ullrich, J. Strapatsas, T. Hemmerle, D. Neri, T. Kessler
Journal: Annals of Oncology (2021)
544P A novel HER2/4-1BB bispecific antibody, YH32367 (ABL105) exerts significant anti-tumor effects through tumor-directed T cell activation
Authors: E. Lee, H. Chung, Y. Lee, E-J. Lee, Y.B. Park, Y. Kim, J.Y. Park, S. Ahn, J. Kim, K.K. Ahn, K. Park, W. Son, D. Yeom, J. Jung, J. Won, S. Oh
Journal: Annals of Oncology (2021)
1081P Hospital variation in cancer treatments and survival outcomes of advanced melanoma patients: Nation-wide quality assurance in the Netherlands
Authors: J.V. Breeschoten, A.J.M. Van den Eertwegh, L. de Wreede, D. Hilarius, E. van Zwet, J.B.A.G. Haanen, C.U. Blank, M. Aarts, F. Van den Berkmortel, J.W.B. de Groot, G.A. Hospers, E. Kapiteijn, D. Piersma, R.S. van Rijn, M. Stevense, A.A.M. Van der Veldt, G. Vreugdenhil, M. Boers-Sonderen, K. Suijkerbuijk, M.W.J.M. Wouters
Journal: Annals of Oncology (2021)
Effects of black cohosh treatment on metastatic markers in the MMTV/neu model of breast cancer
Authors: Mary P. Kotlarczyk, Vicki L. Davis, Manuel J. Jayo
Journal: Cancer Research (2006)

3926   Black cohosh is an herbal supplement used by many women to control the symptoms of menopause, mainly hot flashes. While many view black cohosh as a safe alternative to hormone replacement therapy, there is limited research regarding the effects of black cohosh on breast tumor development and progression. Previous work in our lab has shown that black cohosh treatment (adjusted to correlate with the recommended dose in women) did not alter primary mammary tumor incidence and latency in MMTV/ neu  transgenic mice. However, black cohosh treatment did significantly increase the incidence of metastatic cancer. We have recently confirmed that black cohosh does not alter expression of the  neu  transgene in the normal mammary gland, indicating that the changes in metastatic cancer incidence are not due to the effects of black cohosh on the MMTV promoter. Expression of the endogenous  neu  gene was also unchanged. We are currently investigating metastatic markers to determine how black cohosh is altering tumor progression. Matrix metalloproteinases 2 and 9 (MMP-2, MMP-9) are enzymes involved in degradation of the basement membrane, an important step in the metastatic pathway. Tumor tissues from both control and black cohosh-treated mice that had detectable metastatic mammary tumors and those that had no metastases were analyzed by gelatin zymography to determine expression of MMP-2 and MMP-9. Preliminary results suggest that black cohosh treatment may increase the levels of active MMP-2 and MMP-9 enzymes. Through ongoing analysis of matrix metalloproteinases and additional metastatic and angiogenic factors, we hope to identify specific markers that are altered by black cohosh treatment. This will enable us to better understand how black cohosh is promoting the progression of primary mammary tumors to metastatic cancer. Because the MMTV/ neu  model mimics a common form of human breast cancer (HER2), these markers can then be examined in human samples in order to determine if the effects of black cohosh on metastatic cancer are similar in breast cancer patients.
Single-cell Transcriptomes Reveal Characteristics of MicroRNAs in Gene Expression Noise Reduction
Authors: Tao Hu, Lei Wei, Shuailin Li, Tianrun Cheng, Xuegong Zhang, Xiaowo Wang
Journal: Genomics Proteomics & Bioinformatics (2021)

Abstract Isogenic cells growing in identical environments show cell-to-cell variations because of the stochasticity in gene expression. High levels of variation or noise can disrupt robust gene expression and result in tremendous consequences for cell behaviors. In this work, we showed evidence from single-cell RNA sequencing data analysis that microRNAs (miRNAs) can reduce gene expression noise at the mRNA level in mouse cells. We identified that the miRNA expression level, number of targets, target pool abundance, and miRNA–target interaction strength are the key features contributing to noise repression. miRNAs tend to work together in cooperative subnetworks to repress target noise synergistically in a cell type-specific manner. By building a physical model of post-transcriptional regulation and observing in synthetic gene circuits, we demonstrated that accelerated degradation with elevated transcriptional activation of the miRNA target provides resistance to extrinsic fluctuations. Together, through the integrated analysis of single-cell RNA and miRNA expression profiles, we demonstrated that miRNAs are important post-transcriptional regulators for reducing gene expression noise and conferring robustness to biological processes.
Prevalence of Marfan syndrome, Ehlers-Danlos syndrome, and osteogenesis imperfecta in patients with hidradenitis suppurativa
Authors: Rune Kjærsgaard Andersen, Andrew Strunk, Rachel Tannenbaum, Jurr Boer, Amit Garg, Gregor Jemec
Journal: Journal of the American Academy of Dermatology (2021)
889P Development of a head and neck immune prognostic index (HN-IPI) classification for patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) who received immune checkpoint inhibitors (ICIs)
Authors: Z. Syeed, M. Forster, I. Boukovinas, C. Nutting, D. Carnell, T. Guerrero Urbano, A. Sibtain, N. Kalavrezos, G. Patel, M. Al Bakir, H-T. Arkenau, S. Levva, P. Gonnet, C. Morelli, S. Guerriero, M. Rofei, V. Formica, A. Patrikidou
Journal: Annals of Oncology (2021)
NIMble innovation—a networked model for public antibiotic trials
Authors: Rebecca E Glover, Andrew C Singer, Adam P Roberts, Claas Kirchhelle
Journal: The Lancet Microbe (2021)

Antibiotic research and development is at an inflection point. Faced with ongoing problems with commercial innovation, we argue for a networked public approach to support and coordinate existing research and development initiatives by sustainably moving promising compounds through clinical trials. We propose a global public infrastructure of institutes tasked with (1) conducting all trial stages up to market authorisation, including small-scale compound production; (2) negotiating licensing agreements for global production and distribution by industry partners; and (3) using public purchasing agreements or subscription models to ensure commercially viable drug production at equitable prices. We invite stakeholders to consider our Networked Institute Model's benefits for unblocking the public and private antibiotic pipeline.
Botulinum toxin: endoscopic treatment in fecal incontinence after ileoanal anastomosis
Authors: Nicolas Richard, Paul Basile, Guillaume Gourcerol
Journal: Endoscopy (2021)

Botulinum toxin A is used in gastroparesis treatment [1], esophagus motility disorders [2], and anal fissures [3]. Botulinum toxin A injection after proctectomy was proposed more recently by our team for treating fecal incontinence [4]. Its use in treating fecal incontinence after ileoanal anastomosis has never been studied in humans. We report the first case of ileal botulinum toxin A injections in a human after ileoanal anastomosis.
1694P Coffee and tea consumption (CTC), patient-reported (PRO), and clinical outcomes in a longitudinal study of patients (pts) with breast cancer (BC)
Authors: D. Soldato, J. Havas, D. Presti, P. Lapidari, N. Rassy, B. Pistilli, E. Martin, L. Del Mastro, A-L. Martin, A. Jacquet, C. Coutant, P.H. Cottu, A. Merimèche, F. Lerebours, O. Tredan, L. Vanlemmens, F. André, I. Vaz-Luis, A. Di Meglio
Journal: Annals of Oncology (2021)
1023P A novel microbiome-derived peptide, SG-3-00802 reverses resistance to anti-programmed death protein-1 (PD-1) therapy
Authors: H. Kiefel, D. Haria, J.D. Ravichandar, J. Desnoyer, J. Guagua, S. Lau, J. Lee, E. Rutherford, K. Dabbagh, P. Lal
Journal: Annals of Oncology (2021)
12P The design and development of novel pentaranes: Paving the way to EMT inhibition in triple-negative breast cancer cells
Authors: A.M. Scherbakov, D.I. Salnikova, D.V. Sorokin, Y.V. Kuznetsov, M. Tserfas, I.V. Zavarzin, I.S. Levina
Journal: Annals of Oncology (2021)
Polygenic basis and biomedical consequences of telomere length variation
Authors: Veryan Codd, Qingning Wang, Elias Allara, Crispin Musicha, Stephen Kaptoge, Svetlana Stoma, Tao Jiang, Stephen E. Hamby, Peter S. Braund, Vasiliki Bountziouka, Charley A. Budgeon, Matthew Denniff, Chloe Swinfield, Manolo Papakonstantinou, Shilpi Sheth, Dominika E. Nanus, Sophie C. Warner, Minxian Wang, Amit V. Khera, James Eales, Willem H. Ouwehand, John R. Thompson, Emanuele Di Angelantonio, Angela M. Wood, Adam S. Butterworth, John N. Danesh, Christopher P. Nelson, Nilesh J. Samani
Journal: Nature Genetics (2021)

Abstract Telomeres, the end fragments of chromosomes, play key roles in cellular proliferation and senescence. Here we characterize the genetic architecture of naturally occurring variation in leukocyte telomere length (LTL) and identify causal links between LTL and biomedical phenotypes in 472,174 well-characterized UK Biobank participants. We identified 197 independent sentinel variants associated with LTL at 138 genomic loci (108 new). Genetically determined differences in LTL were associated with multiple biological traits, ranging from height to bone marrow function, as well as several diseases spanning neoplastic, vascular and inflammatory pathologies. Finally, we estimated that, at the age of 40 years, people with an LTL &gt;1 s.d. shorter than the population mean had a 2.5-year-lower life expectancy compared with the group with ≥1 s.d. longer LDL. Overall, we furnish new insights into the genetic regulation of LTL, reveal wide-ranging influences of LTL on physiological traits, diseases and longevity, and provide a powerful resource available to the global research community.
The Drug-Dosing Conundrum in Oncology — When Less Is More
Authors: Mirat Shah, Atiqur Rahman, Marc R. Theoret, Richard Pazdur
Journal: New England Journal of Medicine (2021)

Doses and schedules of oncology drugs are sometimes inadequately characterized before registration trials. The “more is better” paradigm is still used for dose selection, despite the recognition that targeted therapies require alternative approaches to dose optimization.
684P Molecular underpinnings of glandular tropism in metastatic clear cell renal cell carcinoma
Authors: E. Roussel, L. Kinget, A.T.L. Verbiest, J. Zucman-Rossi, G. Couchy, S. Caruso, M. Baldewijns, S. Joniau, H. Van Poppel, M. Albersen, B. Beuselinck
Journal: Annals of Oncology (2021)
1365TiP A phase I/II, open-label study of BBT-176, a triple mutation targeting EGFR TKI, in patients with NSCLC who progressed after prior EGFR TKI therapy
Authors: S.M. Lim, D-W. Kim, J.E. Jung, G. Lee, J-H. Ryou, S-U. Kang, Y-H. Lee, H-J. Shin, S.Y. Yum, E. Yim, S-Y. Lee, J.S. Ahn
Journal: Annals of Oncology (2021)
Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials
Authors: Kevin L Winthrop, Peter Nash, Kunihiro Yamaoka, Eduardo Mysler, Nasser Khan, Heidi S Camp, Yanna Song, Jessica L Suboticki, Jeffrey R Curtis
Journal: Annals of the Rheumatic Diseases (2021)

Background Upadacitinib (UPA) is an oral Janus kinase (JAK) inhibitor approved for the treatment of rheumatoid arthritis (RA). JAK inhibitors have been associated with an increased risk of herpes zoster (HZ) in patients with RA. Objectives To evaluate the incidence and risk factors for HZ in UPA-treated patients with RA from the UPA phase III clinical trial programme. Methods Exposure-adjusted incidence/event rates for HZ were determined in patients receiving UPA (monotherapy or combination therapy) in six randomised phase III trials (data cut-off on 30 June 2020). HZ incidence and event rates were also determined in patients receiving methotrexate (MTX) monotherapy or adalimumab (ADA) + MTX. Multivariable Cox regression analysis was used to identify HZ risk factors in UPA-treated patients. Results A total of 5306 patients were included in this analysis. The incidence rate of HZ/100 patient-years (95% CI) was 0.8 (0.3 to 1.9), 1.1 (0.5 to 1.9), 3.0 (2.6 to 3.5) and 5.3 (4.5 to 6.2), in the MTX monotherapy, ADA + MTX, UPA 15 mg and UPA 30 mg groups, respectively. The majority of HZ cases with UPA (71%) involved a single dermatome. Prior history of HZ and Asian region were HZ risk factors in UPA-treated patients. Conclusion In the UPA phase III RA clinical programme, HZ incidence and event rates were higher with UPA versus ADA + MTX or MTX monotherapy, and higher with the 30 mg versus 15 mg dose. Patients from Asia and those with a history of HZ may be at increased risk of HZ while receiving UPA.
700P Efficacy of sacituzumab govitecan (SG) by trophoblast cell surface antigen 2 (Trop-2) expression in patients (Pts) with metastatic urothelial cancer (mUC)
Authors: Y. Loriot, A.V. Balar, D.P. Petrylak, A. Rezazadeh, P. Grivas, A. Fléchon, R.K. Jain, N. Agarwal, M. Bupathi, P. Barthelemy, P. Beuzeboc, P. Palmbos, C. Kyriakopoulos, D. Pouessel, C.N. Sternberg, Y. Pan, J.M. Jürgensmeier, T. Goswami, S.T. Tagawa
Journal: Annals of Oncology (2021)
Mental health: Staff shortages are causing distressingly long waits for treatment, college warns
Authors: Abi Rimmer
Journal: BMJ (2021)

England has just one consultant psychiatrist for every 12 600 people, and services are unable to meet record demand for treatment, the Royal College of Psychiatrists has said.

At least 1.5 million people in England are waiting for mental health treatment, but a 10th of consultant psychiatrist posts (568 of 5367) are not filled, the college’s 2021 census has shown.1

An analysis conducted by the college in October 2020 found that two fifths of patients waiting for mental health treatment were forced to contact emergency or crisis services before receiving treatment,2 with one in 10 ending up at an emergency department. A quarter of adults who had to wait after their …
807P Multi-centre study of escalated etoposide/cisplatin (Esc-EP) as a novel salvage regimen in advanced/refractory gestational trophoblastic neoplasia
Authors: J. Clark, S. Suyanto, L. Hennah, M. Winter, U. Joneborg, E. Wallin, A. Harry, N. Naban, B. Kaur, X. Aguiar, T. Tin, N. Sarwar, M. Gonzalez, M. Seckl
Journal: Annals of Oncology (2021)
Investigating the association between ALK receptor tyrosine kinase inhibitors and pulmonary arterial hypertension: a disproportionality analysis from the WHO pharmacovigilance database
Authors: Charles Khouri, Alex Hlavaty, Matthieu Roustit, Jean-Luc Cracowski, Marie-Camille Chaumais, Marc Humbert, David Montani
Journal: European Respiratory Journal (2021)

<b>PAH associated with crizotinib seems to be very rare but cases are reported in pharmacovigilance databases with other ALK tyrosine kinases inhibitors, notably lorlatinib. Therefore, the potential emergence of PAH by ALK-TKI needs to be further explored.</b>https://bit.ly/3k9es94
1509MO Adherence to the Food and Drug Administration (FDA) guidance for the co-development of two or more investigational new drugs in phase 1/2 cancer trials
Authors: J.T. Moyers, D. Nguyen, D.S. Hong, E.E. Ileana Dumbrava, S. Fu, D. Karp, A. Naing, S. Pant, F. Janku, S.A. Piha-Paul, J. Rodon, V. Subbiah, A.M. Tsimberidou, F. Meric-Bernstam, T.A. Yap
Journal: Annals of Oncology (2021)
John Hilton Walker
Authors: Alan Craft
Journal: BMJ (2021)

John Hilton Walker, who has died aged 93, was professor of general practice, family and community medicine in Newcastle. Like many of his era he was stung by the remarks of Churchill’s doctor, Lord Moran, who said that general practice was where those who fell off the consultant ladder landed. He was determined to improve its image, starting at the beginning of medical education. In the early 1960s a survey of medical schools in the UK had shown that there was very little, if any, structured teaching and the impression was that general practice was an afterthought. Students in their final year had very short attachments in an unstructured and unsupervised way, where they were shown something of the peculiarities of general practice, with little participation by staff of the medical school. In 1964, as part of a new integrated experiment in medical education, all students in Newcastle were exposed to family and community medicine soon after their arrival in medical school. A group of enthusiastic local GPs were recruited, and all students had regular visits to GP surgeries. They were also given a …
潜在的な心疾患を伴う慢性心房細動に対するメイズ(COX-III)手術の臨床結果の予測因子:心房心外膜マッピングの重要性
Authors: Yagi Y, Mukaida M, Chiba N, Kamata J, Izumoto H, Sasaki T, Kawazoe K
Journal: Circulation (1995)
754P Neoadjuvant chemotherapy followed by interval debulking surgery for advanced epithelial ovarian cancer in Japan - GOTIC-019: A multi-institutional retrospective cohort study
Authors: S. Nagao, J. Tamura, T. Shibutani, M. Miwa, T. Kato, T. Satoh, Y. Takei, N. Kamitani, N. Inoue, K. Nakamura, T. Matsumoto, K. Fujiwara, M. Suzuki
Journal: Annals of Oncology (2021)
Clinical and technical outcomes of patients undergoing endoscopic ultrasound-guided gastroenterostomy using 20-mm vs. 15-mm lumen-apposing metal stents
Authors: Michael Bejjani, Bachir Ghandour, Jose Carlos Subtil, Belén Martínez-Moreno, Reem Z. Sharaiha, Rabindra R. Watson, Thomas E. Kowalski, Petros C. Benias, Matthew T. Huggett, Tobias Weber, Lionel S. D’Souza, Andrea Anderloni, Michael Lajin, Harshit S. Khara, Khanh Do-Cong Pham, Douglas Pleskow, Carlo Fabbri, Jose M. Nieto, Nikhil A. Kumta, Rishi Pawa, Manol Jovani, Mouen A. Khashab
Journal: Endoscopy (2021)

Most studies on endoscopic ultrasound (EUS)-guided gastroenterostomy (EUS-GE) for palliation of malignant gastric outlet obstruction (GOO) utilized a 15-mm lumen-apposing metal stent (LAMS). More recently, a 20-mm LAMS has become available. This study aimed to compare rates of technical and clinical success and adverse events (AEs) in patients undergoing EUS-GE using a 20-mm vs. 15-mm LAMS.Patients who underwent EUS-GE with 15-mm or 20-mm LAMS for malignant GOO during the period from January 2018 to October 2020 were included. The primary outcome was clinical success, defined as an increase in the gastric outlet obstruction score (GOOS) by at least 1 point during follow-up. Secondary outcomes were technical success, maximum tolerated diet, re-intervention rate, and rate/severity of AEs.267 patients (mean age 67 years, 43 % women) with malignant GOO from 19 centers underwent EUS-GE. Clinical success rates were similar for the 15-mm and 20-mm stents (89.2 % [95 %CI 84.2 %-94.2 %] vs. 84.1 % [77.4%-90.6 %], respectively). However, a significantly higher proportion of patients in the 20-mm group tolerated a soft solid/complete diet at the end of follow-up (91.2 % [84.4 %-95.7 %] vs. 81.2 % [73.9 %-87.2 %], P = 0.04). Overall, AEs occurred in 33 patients (12.4 % [8.4 %-16.3 %]), with similar rates for 15-mm and 20-mm stents (12.8 % [7.5 %-18.2 %] vs. 11.8 % [6 %-17.6 %]), including incidence of severe/fatal AEs (2 % [0.4 %-5.8 %] vs. 3.4 % [0.9 %-8.4 %]).The 20-mm and 15-mm LAMS show similar safety and efficacy for patients undergoing EUS-GE for malignant GOO. The 20-mm LAMS allows a more advanced diet and is, thus preferred for EUS-GE.
1473P Gender differences in treatment allocation and survival in a real-world metastatic pancreatic cancer cohort
Authors: E. Pijnappel, M. Schuurman, A.D. Wagner, J.de vos-Geelen, L. van der Geest, J.W.B. de Groot, B. Groot Koerkamp, I. de Hingh, M. Homs, G-J. Creemers, G. Cirkel, H. van Sanvoort, O. Busch, M. Besselink, C. van Eijck, H. Wilmink, H. van Laarhoven
Journal: Annals of Oncology (2021)
Targeting epigenetically maladapted vascular niche alleviates liver fibrosis in nonalcoholic steatohepatitis
Authors: Hua Zhang, Yongyuan Ma, Xinying Cheng, Dongbo Wu, Xingming Huang, Bin Chen, Yafeng Ren, Wei Jiang, Xiaoqiang Tang, Ting Bai, Yutian Chen, Yilin Zhao, Chunxue Zhang, Xia Xiao, Jing Liu, Yue Deng, Tinghong Ye, Lu Chen, Han-Min Liu, Scott L. Friedman, Liping Chen, Bi-Sen Ding, Zhongwei Cao
Journal: Science Translational Medicine (2021)

Epigenetic targeting of the maladaptive vascular niche in fibrotic liver blocks fibrosis by alleviating fibrogenic angiocrine IGFBP7 and ADAMTS1.
448P Efficacy of combinations of BRAF inhibitors and anti-EGFR antibodies in metastatic colorectal carcinoma (mCRC) patients with mBRAF in the real clinical practice
Authors: M. Fedyanin, H. Elsnukaeva, I. Demidova, D. Stroyakovskiy, Y. Shelygin, A. Tsukanov, M. Panina, F. Moiseenko, E. Karpenko, L. Bolotina, A. Kudryavtseva, M. Filipenko, I. Oskorbin, L.Y. Vladimirova, N.N. Timoshkina, O.I. Kit, A. Stroganova, S. Dranko, A. Tryakin, S. Tjulandin
Journal: Annals of Oncology (2021)
233P Association of quality of life (QOL) with overall survival (OS) in patients (pts) with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA-3 (ML-3) and ML-7 trials
Authors: P.A. Fasching, N. Harbeck, G. Jerusalem, M.A. Colleoni, P. Neven, F. Franke, M. De Laurentiis, D. Tripathy, M. Martin, G. Babu, D. Yardley, P. Wheatley-Price, A. Chan, R. Villanueva Vazquez, A. Nusch, E. Gu, H. Hu, P. Pathak, A. Thuerigen, A. Bardia
Journal: Annals of Oncology (2021)
555TiP A first-in-human trial of the integrin beta-6-targeted antibody–drug conjugate, SGN-B6A, in patients with advanced solid tumors
Authors: E. Calvo, A. Hollebecque, A. Dowlati, S.A. Piha-Paul, V. Galvao, J. Lopez, K. Sehgal, B. Bockorny, F. Braiteh, S. Peters, R.E. Sanborn, P. Zhou, N. Nazarenko, A. Patnaik
Journal: Annals of Oncology (2021)
670P Cabozantinib associated with concomitant radiotherapy or a bone targeted agent (multimodal approach, results from the CABOREAL study post-hoc analysis)
Authors: M. Gross-Goupil, A. Fléchon, L. Mourey, D. Topart, G. Gravis, S.M. Oudard, J-M. Tourani, L. Geoffrois, E. Meriaux, A. Thiery-Vuillemin, P. Barthelemy, S. Ladoire, B. Laguerre, L. Zara, V. Perrot, B. Escudier, L. Albiges
Journal: Annals of Oncology (2021)